Pfizer Doesn’t Like Crossover Design For Placebo Patients In COVID-19 Vaccine Trial
Only vaccinating the placebo group would be much easier once the US FDA grants an EUA for its coronavirus vaccine, Pfizer says.
You may also be interested in...
Pfizer relies on investigators to determine when prioritization recommendations apply, Moderna offers unblinding to everyone.
US FDA’s outside advisors say Moderna should offer vaccine to placebo-arm patients when they are eligible, the same plan adopted for the Pfizer/BioNTech COVID-19 vaccine.
After the various turnovers, the panel will be one person smaller, and while the agenda includes familiar topics, including maintaining placebo controls after a vaccine is available, the presentation order will be different.